Different points on the research spectrum were under the microscope at the Wharton Health Care Business Conference last month as two panels of biotech, pharmaceutical and investment leaders discussed the state of R&D among big pharmaceuticals and the progress of stem cell research. While disappointing results in both sectors have dominated the news lately, panelists at each session also noted some promising developments -- and causes for optimism -- in their respective fields.
Economics | Health Economics | Social and Behavioral Sciences
Copyright Owner and Holder
Copyright © Singapore Management University 2012
Industry Leaders Debate Big Pharma R&D (Too Little Hope?) and Stem Cell Research (Too Much hype?). (2006). Knowledge@SMU.
Available at: http://ink.library.smu.edu.sg/ksmu/98